Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I received this email as well Monday or Tuesday . I can’t private message but if you want to send me your email privately, I can forward it to you to view.
How does this relate to Anavex?
NPHC is 2 weeks away from being current on two 10-Qs and the 10-K. EOM.
Great call as usual!
Please stop with your gloom and doom “down 95%” take. It’s played out. This stock ran from the trips to .006’s in a short period of time. Anyone who did not sell after that much of a gain or bought after that much of a gain, simply made a mistake. It happens hundreds of times a day in the market. For you to portray this company was steadily at higher prices and stable for an extended period of time and is now down 95% is misleading and disingenuous.
I think they bought in Q4 so it could be the correct calculation.
Wish he would do something illegal so the SEC would go after him and force him to let someone else take over!
I agree with many here that he is nothing more than a liar but I find it hard to believe not one product has sold in months. The counter on the website must not be working properly. Has anyone tried to order to see if it changes? If that number is accurate though then I digress, I’ve already written this loss off in my head.
Glad to see you looking into this again!
192400
Market is absolutely rigged. I’ve never seen a gap here, not fill in 4 years though. Yes, we are approaching uncharted territory with this company and have potentially pivotal upcoming news and developments forthcoming. I’m not saying we are going under $2 tomorrow lol but there is a gap on the charts that most likely will fill. It’s not $1.50 seesh guys, it’s $2.80ish. Yes, we could break away and never return but how many times have we been let down or disappointed after a smaller conference and retraced temporarily? Most every time. Tomorrow may very well be different and new news is released and we rise. But who is to say we don’t drift down to fill the gap immediately or after a rise until further news or the conference this summer? He stated $2.83 was coming, I simply agreed. We could have great news or no news but odds with this stock is that the gap will fill then we will continue to rise. I’m long and trade the lull months. I don’t expect much tomorrow that longs don’t already know. I’m about done trading, just looking to add closer to the 200 day now that we seem to be progressing appropriately.
If you are long and not trading obviously it doesn’t matter. Gaps usually fill, not always but AVXL typically does fill them. If he is correct then that should bode well for all, gap fills tomorrow then we rise with all of the expected upcoming news.
Regardless if that happens, there is a gap to fill so it will retrace back down towards $2.80 as he stated eventually.
Are you on Facebook? We have a great page of posters that are moderated appropriately. I don’t have private messages unless it’s Friday happy hour but you can send me your info anyways and I can add you or just search Anavex Longs Investors or Anavex Life Sciences Investor Forum and request an admission. Please consider joining the pages and the chats, they’d love to have you since most are not aware of your forum.
Nothing to say unfortunately. I’ve emailed him several times directly about marketing and social media exposure/influence and no response. He’s a joke. But I did just buy some shares to lower my cost basis drastically. Accidentally bought too much though. Will wait this out a few more years for years if necessary. All you can do at this point or sell and move on.
You are very welcome! You do a great job of ignoring the handful of posters who dismiss your work though. I just wanted to say, there are many more of us in the shadows who appreciate your time and efforts so please don’t stop posting there or let them ever discourage you. Unfortunately, so many people on that board have been underwater for years and at this point their only concern is for a quick fix and hoping to wake up one day to a $50 share price. They have been holding and posting daily for years and are just simply bored. They pick on posters who post things they either are unfamiliar with or do not understand as you alluded to...just to pass time until we have news so don’t take it personal. I’ve followed this group for awhile at a distance, most of everyone’s knowledge is above my capabilities though. I just enjoy reading the threads. I’ve only traded AVXL a handful of times the past two-three years to help pass the slow months. My core accounts are still underwater but thank you all for the information, it’s definitely helped me trade this some the past three months!
Don’t listen to those guys over on the AVXL page, you do great work. Keep it up!
There you go!
From Facebook:
“Nyloxin to appear at Talladega!
Nyloxin for Chronic Pain Relief is featured on the "Nyloxin/K&L Ready Mix truck no. 12 of Tanner Thorson at Talladega speedway this weekend.”
https://www.youngsmotorsports.com/news/young-s-motorsports-takes-three-trucks-to-talladega
Has it been stated that John Pauly, the intern CEO of Healthwarehouse last year has been on our board since November? My apologies if I’ve missed it or it’s not the same Premier. Obviously, it hasn’t done a thing for this company I was just curious your thoughts on the relationship?
Count me in as well!
From Post #53398
Hartman: (814) 786-8849
Felder: (724) 979-1902
Borza: (586) 481-5646
Dear Shareholders,
Greetings From The CEO and Staff at Premier Biomedical!
It has been a very busy and eventful quarter for Premier Biomedical.
Finance and Stock Performance
Recent actions by FINRA whereby they notified major trading houses to begin phasing out trading of sub-penny stocks has caused our principal lenders to threaten to eliminate their financial support for our company.
The problem for the company's position was the issued and outstanding shares (those in circulation) represented approximately 70% of the authorized shares level. In addition, trusted investor relations/public relations experts advised us that our sub-penny status was a major negative factor to prospective stockholders to invest in the company. Our own observation was that very favorable news contained in press releases was ignored or produced no effect on the stock price.
As a result, we concluded that it was the best interests of the company and its stockholders to initiate a reverse split. stock-investment-pennies.jpg
Reverse splits can be either very good or very bad for a company, depending on the design of the action. In order to insure a beneficial split for our shareholders and the company, we instituted actions to elevate the resultant stock price to a level in the range of $0.50 - $1.00, significantly reducing our outstanding shares to approximately 3 million shares while maintaining the authorized number of shares at 1 billion shares. We may never need that level of authorized shares, but it gives us a substantial margin for potential future corporate actions, such as joint ventures, partnerships, etc.
Our trusted IR/PR industry sources advised us that this action could produce substantial upward pressure on our stock price as a result of significant product innovations, such as our new line of extra strength relief products, and new patent applications in the Biologics area, extensive media coverage, such as Uptick Newswire, Money TV, and New to the Street.
Last year, we launched our line of topical pain relief products. During the year, we experienced a number of set-backs to our sales efforts, namely prevented from advertising on Google and Facebook by their outdated terms of service that don't allow legal hemp-derived CBD products to be advertised on their platforms.
Similarly, we were barred from selling on Amazon for the same reason.
Despite these setbacks, we managed to register nearly $100,000 in sales of our topical pain relief products in 2017, and plan a significant increase in 2018 as a result of new products, extensive marketing efforts, and direct distribution to pharmacies, healthcare facilities, the military, and the sports industry.
Business Structure
In the first quarter of 2018, the Board of Directors approved the addition of sepia-handshake-header.jpg John Pauly to our board. His appointment brings valuable pharmaceutical retail experience and connections to our BoD.
Immunotherapy and Biologics.
Although a large part of our company has been focused on developing and managing the fledgling Pain Management portion of the business, development still continues in the Immunotherapy and Biologics sector with the filing of a patent application for a method to greatly reduce the aging process. This treatment process is an off-shoot of our patented extracorporeal treatment technology.
We also issued a press release concerning a patent application for the use of lasers or similar emissive energy technology as a means to eliminate disease cytokines in an extracorporeal process.
Pain Management.
This past quarter, we shipped our first inventory of products to Health Warehouse for sale via their mail order pharmacy.
Carl Eller, President of the NFL Players Association, presented our Pain Relief Meds products at a dinner and breakfast held as part of the Super Bowl week pre-game activities for active and retired NFL players.
We sent sample products to the Philippines with Dr. Reyes on his trip there in February, seeking to elevate interest in our products. We are awaiting possible purchase orders.
Samples of our topical pain relief products were supplied to officials at the U.S. Department of Defense (DOD) for evaluation as a possible substitute for opioid pain medications, thereby eliminating the addictive effects of opioid use. The initial evaluation has been positive and are continuing discussions to secure a possible purchase order.
This quarter, we made the decision to expand our product offerings to include a line of Extra Strength Products which have now been designed, developed, and committed to production.
The new Extra Strength topical pain relief products are the result of feedback from those with aches and pains associated with an active lifestyle, and those with higher levels of occasional or chronic pain.
In addition to our topical skin patch which contains 50mg of CBD (compared to our principal competition at 40mg CBD) we will soon be marketing these higher concentration CBD products:
Sage scented Oil-Based Roll-On at 200mg CBD vs competition at 100mg, and our standard roll-on at 150mg;
Sage scented Oil-Based Spray with 500mg CBD vs competition at 100mg CBD and our standard wintergreen scented spray at 150mg;
Sage scented Ointment with 500mg CBD in a 1 oz jar, compared to our current wintergreen scented ointment with 150mg in a 2 oz. jar.
These new Extra Strength products will launch at this year's Fitness Equipment Expo, Sorinex Summer Strong 2018 event, in Lexington, SC
We are in the process of producing sample "Sachets" - small packets containing a small amount of our 500mg/oz ointment for people to try. These samples will be distributed through various sales channels in an effort to increase our customer base.
An integral part of our effort to focus on expanding sales and increase marketing efforts, we hired a National Sales Director and secured agreements with sales managers in the West, Midwest, and two in the South.
To support this sales network, we have developed a three-tier sales incentive program with a Sales Director, Sales Managers and Sales Personnel.
In addition to our sales network, we continue to expand our network of retailers and this quarter reached agreement with Okeechobee Discount Drugs to handle our products.
Investor/Public Relations Programs.
In our continuing efforts to broaden our company exposure to the investing public I was interviewed on Uptick Newswire's "Stock Day" radio broadcast/podcast twice during the first quarter.
In addition, I appeared on "New-To-The-Street", Fox Business, and "Money TV".
This quarter, we continued to utilize the services of G.S. Whitney of Dallas, TX to coordinate our IR/PR services.
SUMMARY
From the beginning, we recognized that we would never be able to raise enough money to develop an anti-cancer drug completely on our own and certify it through the FDA. We always recognized that we would have to obtain an established, large pharmaceutical partner. Out of necessity, our recent action to shelve our very promising anti-cancer drug while continuing to prepare patent applications in the use of lasers to eliminate disease antigens/cytokines and to develop anti-aging methodologies were intended to increase our intellectual property and to make us more attractive as a company to large investors/ pharmaceutical partners.
Meanwhile, we have developed a line of topical pain relief products that are industry-leading. Our intent is to make this business self-sustaining in 2018 by supplementing our internet sales with a massive expansion of our direct sales to clinics, pharmacies, healthcare facilities, the military, sports industry, etc. We anticipate significant expansion of our direct sales force following the Summer Strong event in the middle of May.
We received several inadequate offers to purchase one portion of the company or the other, but we believe that it is not in the best interests of the company, or the stockholders, to split the company at this time. We were concerned about the current dilution of the company and have implemented actions to increase our stock price, re-establish our position as an OTCQB market company, and make it more attractive to investors, both large and small.
We believe that the current and planned product mix in the topical pain relief business offers an excellent alternative to dangerous opioid pain killers. National published statistics indicate that about 200 people per day are dying from complications linked to opioid drug use. We intend to investigate contact with state and national government administrations to promote our products as a viable alternative to opioids.
I can personally attest to the effectiveness of these new extra strength topical pain relief products in relieving my own pain. Testimonies from other satisfied users of our current products can be found on our website, www.painreliefmeds.com.
Thank you for your patience and support.
Sincerely,
William A. Hartman
President and CEO
Premier Biomedical Inc.
(724) 633-7033
PR@premierbiomedical.com
http://www.premierbiomedical.com/
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.
Contact
Premier Biomedical, Inc.
info@premierbiomedical.com
Glad to see you hear as well! Love your contributions, sorry for the misunderstanding yesterday!
Does it matter if it was paid or not? It’s great exposure, what more could you ask for?
CEO UPDATE LETTER - January, 2018
Dear Shareholders,
Greetings From The CEO and Staff at Premier Biomedical!
It has been a very busy and eventful quarter, and an exceptionally fruitful year, for Premier Biomedical.
Finance and Stock Performance
Financing secured earlier this year has enabled the company to pivot from a pure cancer R&D company (which would remain totally dependent on borrowed money) to a revenue-producing entity with all-natural topical pain relief products.
Recently our stock was moved to OTC Pink from OTCQB. What does this mean to the business? In effect, nothing. We will continue to be a fully reporting company with audited financial statements. The only negative side-effect is that it may become more difficult to borrow money, but our current strategy is to become self-funding as soon as possible, and assume debt only when absolutely necessary.
By continuing all financial controls, auditing and reporting, our transition back to OTCQB or other exchanges will be facilitated.
Business Structure
In the third quarter of 2016, faced with a high debt load and a depressed stock price, we were forced to explore options where we could quickly transition to a revenue-producing entity.
Recognizing the severity of the national crisis of opioid-related drug overdose deaths, we determined that this was a potentially large market for an opioid alternative. After extensive consideration by our technical staff, we decided that topical hemp oil products were a potential solution to address this pressing national need.
Another advantage of topical hemp oil products is that they could be developed, produced and marketed in relatively short time frame in a very cost effective manner. We also decided that our product focus would be limited to all-natural, 50-state legal, industrial hemp oil products.
Very early in 2017, we launched our e-commerce website to sell our first product, a 96-hour topical hemp oil skin patch. During the year, we grew our product line-up to a total of five topical hemp oil skin products (a 150mg, 10 ml oil-based roll-on, a 120mg, 10 ml water-based roll-on, a 150mg, 30ml spray and a 150mg, 2 oz. ointment).
In the fourth quarter, we finalized an agreement with Carl Eller, President of the NFL Retired Players Association. We hope to develop this relationship into an entrée to current and retired professional sports personnel.
Dr. Patricio Reyes, our Chief Medical and Technical Officer, is currently Chief Medical Officer to the NFL Retired Players Association and is on the neurology staff at the Phoenix VA Hospital. Dr. Reyes took a sampling of our products and an investor presentation of the company to the Philippines last week with the intent of introducing our company and products to the Philippines medical community.
In 2018, we intend to focus on the steps necessary to increase the number of major distributors handling our broad topical pain relief product line-up. Our recent partnership with HealthWarehouse is a major step forward to establishing similar relationships with pharmacies, clinics, physicians' offices, senior care facilities, etc.
As we move forward into 2018, we will be dramatically increasing our sales network through the addition of experienced pharmaceutical representatives. We are in the process of negotiating agreements to build a sales structure, starting with an experienced National Sales Director (already identified). We will be rolling out this structure regionally and expanding and improving it as we go. Updates on our progress in this effort will be provided periodically.
We believe that increased product exposure and sales and the resultant revenue generation - which are the fundamentals of building a good business -- will lead to a stock resurgence.
Immunotherapy and Biologics.
We continue to actively seek a partner for our cancer research technology development. We would consider any proposal, including partnership, licensing or sale that represents value for our investors.
We have declined several offers that were not in the best interest of our shareholders. We have a very promising anti-cancer drug which, in animal tests, has outperformed chemo therapy and competitive drugs currently on the market. These results have been peer-reviewed in prestigious cancer journal articles. We believe this product has significant value, and should be adequately recognized in any potential agreement.
Pain Management.
Currently there is a crisis in this country where 60 -70,000 people die annually from drug over-doses linked to prescription pain medications. We believe that this environment provides a catalyst for the growth of our all-natural, effective, topical pain relief products.
An industry study has projected the topical pain relief products market could exceed $5 billion annually by the year 2025.
We surveyed the principal competitors' product offerings and developed proprietary formulations for our initial product, a 96-hour, 50mg hemp oil topical skin patch, as well as the four additional products introduced in 2017. Customers have reported all of these products as being effective in relieving a variety of pains and discomfort.
We initiated the direct sale of our products in January of 2017 via our website, www.painreliefmeds.com. We then branched out to local pharmacies and pain clinics. We recently completed negotiations and cemented an agreement with HealthWarehouse, the largest on-line cash-pharmacy in the nation, to market and distribute our products.
We have received orders for our products from the UK, France, Canada, Mexico, Australia, and the Netherlands. We believe this off-shore exposure will continue and possibly result in establishing overseas distributorships.
Investor/Public Relations Programs.
We have signed an agreement with the New York investor relations firm, New To The Street. I completed an extensive interview in December, which will be aired January 28, 2018, at 1:30 PM EST. This program is part of the Fox Business Network which has a potential audience of 90 million homes. I will appear in five additional segments in 2018, and we will notify our stockholders via our email network.
We will continue our relationship with Uptick Newswire and present corporate updates approximately every six weeks on their network and via press releases.
We continue our relationship with G S Whitney who has done very good investor relations work in presenting the company to its network of investors worldwide.
SUMMARY
This past year, we pivoted the company from a pure R&D focus to a sales-generating product line-up of topical pain relievers which we believe offer superior performance at a competitive price. All of our products are non-narcotic, all-natural, pesticide- and solvent-free, 50-state legal and drug test safe.
Testimonials from our customers indicate effective pain relief for a variety of conditions, including polymyalgia, fibromyalgia, arthritis; neuropathy, migraines, muscle aches, phantom limb pain, etc. (See the Testimonials section on our website Home page, www.painreliefmeds.com).
Developing our sales channels in 2018 is expected to broaden our distribution reach.
We partnered with HealthWarehouse to expand sales reach and to fight opioid abuse. We believe this relationship could provide access to many other entities, including senior centers, pharmacies, physicians and hospitals, chiropractors and pain clinics.
The addition of Carl Eller provides access for our products to the sports industry.
This business would not be possible without the support, dedication and major contributions of all of the people in our organization. Our continued acquisition of superior talent demonstrates a commitment by the staff and the company to our collective future.
We thank you, our investors and loyal stockholders, and pledge that we will continue our efforts on your behalf. We thank you for your patience and continued support.
Sincerely,
William A. Hartman
President and CEO
Premier Biomedical Inc.
(724) 633-7033
PR@premierbiomedical.com
http://www.premierbiomedical.com/
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.
Contact
Premier Biomedical, Inc.
info@premierbiomedical.com
You are just so savvy!!
This augments Premier's existing internet sales through their website, www.painreliefmeds.com, and other direct outlets announced in earlier press releases. The agreement covers not only Premier's existing five pain relief products, but also those planned for the future. The deal also includes the right of HealthWarehouse.com to advertise these products in their catalogs.
Premier Biomedical's existing topical pain
relief products include a 96-hour topical skin patch, oil-based and water-based roll-
ons, an oil-based spray and the newly introduced oil-based ointment. All of Premier's products are made from all-natural, non-GMO, solvent- and pesticide-free ingredients.
Joe Peters, CEO of HealthWarehouse.com, Inc., stated, "People suffering with pain desperately need an alternative to opioid treatment. HealthWarehouse acts as an advocate to help consumers make their health conditions more manageable by increasing the accessibility of prescription and OTC products through lower prices and online access. Premier Biomedical's complete line of pain relief products provides an affordable, high quality, pain relief alternative to our customer base."
William A. Hartman, President & CEO of Premier Biomedical, Inc., stated, "We are very excited that we have been able to secure HealthWarehouse as a partner to provide these opioid alternative pain relief products to a much wider customer base. Once people try our products, they will agree that they outperform every other competitive product in relieving pain and suffering, without the dangerous and addictive side-effects associated with opioids."
Hartman continued, "This represents a significant increase in our business potential, and we look forward to an expansion of sales now, and in the future."
Premier Biomedical and HealthWarehouse Team Up to Fight Opioid Pain Medication Abuse
Jackson Center, PA, January 11, 2018 -- Premier Biomedical, Inc. (OTC: "BIEI ") announced the signing of an agreement with HealthWarehouse.com, Inc. (OTC: "HEWA") to market, sell and distribute Premier's topical pain relief products. HealthWarehouse.com is the nation's largest on-line distributor of prescription and over-the-counter drugs and Porcelain mortar with rx symbol and fresh herbs health supplements!
Count me in for some!
According to social media*
They are there